ÐÂÎÅÖÐÐÄ
News Center
Ê׸öÀֳɵÄС·Ö×Ó¿Ú·þ¿¹Ñª¹ÜÌìÉúÒ©ÎïÍŽá¼Æ»®£¡°²ÂÞÌæÄáÍ»ÆÆÄÔ½ºÖÊÁöÖÎÁÆÀ§¾Ö
Ðû²¼Ê±¼ä£º2025-05-31
.png/%E5%A4%B4%E5%9B%BE(1)__600x279.png)
Ê׸ö»ñµÃÀֳɵÄС·Ö×Ó¿Ú·þ¿¹Ñª¹ÜÌìÉúÒ©ÎïÍŽá¼Æ»®Ð§¹ûÐû²¼£¡ÍâµØʱ¼ä5ÔÂ30ÈÕ£¬ £¬£¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾£¨1177.HK£©ÔÚASCOÄê»áÒÔ×îÐÂÖØ°õÕªÒª(LBA)µÄÐÎʽ£¬ £¬£¬£¬£¬£¬È«ÇòÊ×·¢ÑÎËá°²ÂÞÌæÄὺÄÒÍŽáSTUPP¼Æ»®ÓÃÓÚÐÂÕï¶ÏµÄÄÔ½ºÖÊÁöÖÎÁƵÄÁÙ´²Ñо¿Í»ÆÆÐÔЧ¹û——mPFSΪ9.89¸öÔ£¬ £¬£¬£¬£¬£¬¼²²¡Ï£Íû»òéæÃüΣº¦½µµÍ41%£¬ £¬£¬£¬£¬£¬ÓÐÍûÖúÁ¦Í»ÆÆÁÙ´²GBM»¼ÕßÉúÑÄÄæ¾³¡£ ¡£¡£¡£¡£¡£
£¨³ÂæÂæ½ÌÊÚÔÚ´ó»áÏÖ³¡×÷±¨¸æ£©
Ó¦¶ÔGBMÁÙ´²À§¾Ö£¬ £¬£¬£¬£¬£¬°²ÂÞÌæÄáµãÁÁ¾ÈÖÎÊï¹â
½ºÖÊĸϸ°ûÁö£¨GBM£©ÊÇ×î³£¼ûµÄÇÖÏ®ÐÔÔ·¢ÐÔ¶ñÐÔÄÔÖ×ÁöÖ®Ò»£¬ £¬£¬£¬£¬£¬»¼ÕßÖÐλÉúÑÄÆÚȱ·¦2Ä꣬ £¬£¬£¬£¬£¬ÇÒ5ÄêÉúÑÄÂʽö10%[1-2]¡£ ¡£¡£¡£¡£¡£ÏÖÔÚ£¬ £¬£¬£¬£¬£¬½ºÖÊĸϸ°ûÁöµÄÒ»ÏßÖÎÁƼƻ®ÎªSTUPP¼Æ»®£¬ £¬£¬£¬£¬£¬¼´ÊÖÊõÇгýÖ×Áöºó·ÅÁÆ£¨RT£©ÓëÌæĪßò°·(TMZ)»¯ÁÆÏàÍŽᡣ ¡£¡£¡£¡£¡£¸Ã¼Æ»®ËäÄÜ×ÊÖú»¼Õ߶ÌÆÚ¿ØÖƲ¡Ç飬 £¬£¬£¬£¬£¬µ«ÏÕЩËùÓл¼Õß¾ù»á¸´·¢[3]¡£ ¡£¡£¡£¡£¡£¶ø¸´·¢ÖÎÁÆÃæÁÙ×ÅË«ÖØÌôÕ½£º¸ßÁ仼ÕßÒòÖØ´óÉñ¾Ö¢×´³£±»ÁÙ´²ÊÔÑéɨ³ý£¬ £¬£¬£¬£¬£¬ÑªÄÔÆÁÕϵ¼ÖÂÒ©ÎïÄÑÒÔÓÐÓõÝËÍÇÒÄÑÒÔƽºâϸ°û¶¾Ò©ÎïµÄÖÎÁƼÁÁ¿Ó붾ÐÔ[4]¡£ ¡£¡£¡£¡£¡£Òò´Ë£¬ £¬£¬£¬£¬£¬ÁÙ´²ÆÈÇÐÐèÒª¿ª·¢ÐͬÖÎÁÆÕ½ÂÔ£¬ £¬£¬£¬£¬£¬ÒÔÍ»ÆÆGBMÉúÑÄÄæ¾³¡£ ¡£¡£¡£¡£¡£
Ѫ¹ÜÔöÉúÊÇGBMµÄÒ»¸öÏÔÖøÌØÕ÷£¬ £¬£¬£¬£¬£¬GBM»¼ÕßµÄѪ¹Ü±ÈÕý³£Ñª¹Ü¸ü´Ö£¬ £¬£¬£¬£¬£¬ÇÒ×ݺύ֯¡¢¹Ü¾¶Òì³£¡¢Éø͸ÐԸߣ¬ £¬£¬£¬£¬£¬²¢ÐγÉÒì³£·ÖÖ§¡£ ¡£¡£¡£¡£¡£¿£¿£¿£¿£¿£¿£¿£¿¹Ñª¹ÜÌìÉúÒ©ÎïÄÜʹÖ×Áöϸ°ûѪ¹ÜÕý³£»£»£»£»£»¯£¬ £¬£¬£¬£¬£¬ÓÐÍû³ÉΪÁÙ´²Ö÷ÒªÕ½ÂÔ¡£ ¡£¡£¡£¡£¡£ÐÂÐͶà°ÐµãÒÖÖƼÁ°²ÂÞÌæÄá¿Éͬʱ°ÐÏòVEGFR¡¢FGFR¼°PDGFRµÈͨ·£¬ £¬£¬£¬£¬£¬ÒÖÖÆÖ×ÁöѪ¹ÜÌìÉúºÍÔöÖ³¡£ ¡£¡£¡£¡£¡£
±¾´ÎÐû²¼Ð§¹ûµÄÊÇÒ»Ïî°²ÂÞÌæÄáÍŽáSTUPP¼Æ»®±ÈÕÕο½å¼ÁÖÎÁÆÐÂÕï¶ÏÄÔ½ºÖÊÁö»¼ÕߵĶàÖÐÐÄ¡¢Ëæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕÕµÄÁÙ´²Ñо¿£¬ £¬£¬£¬£¬£¬Ö¼ÔÚÈÃÐÂÕï¶ÏµÄÄÔ½ºÖÊÁö»¼Õ߸üÔçÊÜÒæ¡£ ¡£¡£¡£¡£¡£ÔçÔÚ2021ÄêµÄASCOÄê»á£¬ £¬£¬£¬£¬£¬ÒѾÐû²¼±¾Ñо¿µÄÔ¤ÊÔÑ飨NCT04119674£©Ð§¹û£¬ £¬£¬£¬£¬£¬Ö¤Êµ°²ÂÞÌæÄáÍŽáSTUPP¼Æ»®ÔÚÖÎÁÆÐÂÕï¶ÏGBM»¼ÕßÖлñÒæÏÔ×Å[5]¡£ ¡£¡£¡£¡£¡£
ÉúÑÄ»ñÒæÑÓÉì4¸öÔ£¬ £¬£¬£¬£¬£¬¼²²¡Ï£Íû/éæÃüΣº¦½µµÍ41%
±¾´ÎÈë×éµÄÐÂÕï¶Ï½ºÖÊĸϸ°ûÁö»¼Õߣ¬ £¬£¬£¬£¬£¬ÒÔ1:1µÄ±ÈÀýËæ»ú½ÓÊÜ°²ÂÞÌæÄá»òο½å¼Áͬʱ½ÓÊÜSTUPP¼Æ»®ÖÎÁÆ¡£ ¡£¡£¡£¡£¡£·ÅÁƺó»¼Õß¼ÌÐø½ÓÊÜÌæĪßò°·ºÍ°²ÂÞÌæÄá/ο½å¼Á£¬ £¬£¬£¬£¬£¬Ö±µ½¼²²¡Ï£Íû»ò·ºÆ𲻿ɽÓÊܵĶ¾ÐÔ¡£ ¡£¡£¡£¡£¡£
×èÖ¹2024Äê12ÔÂ6ÈÕ£¬ £¬£¬£¬£¬£¬Ñо¿¹²ÄÉÈë153Ãû»¼Õߣ¬ £¬£¬£¬£¬£¬Á½×éÊÜÊÔÕß»ùÏßÌØÕ÷»ù±¾Æ½ºâ¡£ ¡£¡£¡£¡£¡£Ñо¿Ð§¹û[6]ÏÔʾ£º
¡ñÓÐÓÃÐÔ·½Ã棺°²ÂÞÌæÄá×é×ÔÁ¦Êý¾ÝίԱ»á£¨IRC£©ÆÀ¹ÀµÄÖÐλÎÞÏ£ÍûÉúÑÄÆÚ£¨mPFS£©´ï9.89¸öÔ£¨95% CI 9.10-11.56£©£¬ £¬£¬£¬£¬£¬½Ïο½å¼Á×飨5.85¸öÔ£©ÏÔÖøÌáÉý£¬ £¬£¬£¬£¬£¬¼²²¡Ï£Íû»òéæÃüΣº¦½µµÍ41%£¨HR=0.59£¬ £¬£¬£¬£¬£¬p=0.0018£©¡£ ¡£¡£¡£¡£¡£ÖµµÃ¹Ø×¢µÄÊÇ£¬ £¬£¬£¬£¬£¬¹ØÓÚMGMT¼×»ù»¯»¼ÕßȺÌ壬 £¬£¬£¬£¬£¬°²ÂÞÌæÄá×émOSËäÈ»ÉÐδµÖ´ï£¬ £¬£¬£¬£¬£¬µ«Ïà½ÏÓÚο½å¼Á×飬 £¬£¬£¬£¬£¬éæÃüΣº¦ÒÑÏÔÖø½µµÍ69%£¨HR=0.31£¬ £¬£¬£¬£¬£¬p=0.0093£©¡£ ¡£¡£¡£¡£¡£
¡ñÇå¾²ÐÔ·½Ã棺3¼¶¼°ÒÔÉÏÓë°²ÂÞÌæÄá»òο½å¼ÁÏà¹ØµÄÖÎÁÆʱ´úÑÏÖز»Á¼ÊÂÎñ±¬·¢Âʵͣ¬ £¬£¬£¬£¬£¬»®·ÖΪ16.8%ºÍ9.2%¡£ ¡£¡£¡£¡£¡£°²ÂÞÌæÄá×éµÄ²»Á¼·´Ó¦Ö÷ÒªÊǸßѪѹ£¬ £¬£¬£¬£¬£¬µ«¾ù¿É¿Ø£¬ £¬£¬£¬£¬£¬Î´ÐÂÔöÇå¾²ÐÔÐźţ¬ £¬£¬£¬£¬£¬Ö§³Öºã¾ÃÓÃÒ©¡£ ¡£¡£¡£¡£¡£
ÕâһͻÆÆÐÔЧ¹û£¬ £¬£¬£¬£¬£¬Ê×´Î֤ʵÁËС·Ö×Ó¶à°Ðµã¿¹Ñª¹ÜÌìÉúÒ©Îï°²ÂÞÌæÄáÍŽá±ê×¼ÖÎÁƼƻ®ÔÚÐÂÕï¶Ï½ºÖÊĸϸ°ûÁö£¨GBM£©ÖÎÁÆÖеÄÐͬÔöЧ¼ÛÖµ£¬ £¬£¬£¬£¬£¬±ê¼Çןüƻ®³ÉΪÊ׸ö»ñµÃÀֳɵÄС·Ö×Ó¿Ú·þ¿¹Ñª¹ÜÌìÉúÒ©ÎïÍŽá¼Æ»®¡£ ¡£¡£¡£¡£¡£
%20%E6%8B%B7%E8%B4%9D.png/%E9%95%BF%E5%9B%BEASCC2(1)%20%E6%8B%B7%E8%B4%9D__600x276.png)
%20%E6%8B%B7%E8%B4%9D2.png/%E9%95%BF%E5%9B%BEASCC2(1)%20%E6%8B%B7%E8%B4%9D2__600x276.png)
×÷ΪÊ׸öÀֳɵÄС·Ö×Ó¿¹Ñª¹ÜÐͬÖÎÁƼƻ®£¬ £¬£¬£¬£¬£¬°²ÂÞÌæÄáÍŽáSTUPP¼Æ»®ÀÖ³ÉÆƽâÁË¿¹Ñª¹ÜÖÎÁƵÄѪÄÔÆÁÕÏÀ§¾Ö¡£ ¡£¡£¡£¡£¡£Ïà±È¹Å°å·Å»¯ÁÆ£¬ £¬£¬£¬£¬£¬ÒÀ¸½Ð¡·Ö×Ó¶à°ÐµãÌØÕ÷£¨Í¬Ê±ÒÖÖÆVEGFR/FGFR/PDGFR£©£¬ £¬£¬£¬£¬£¬°²ÂÞÌæÄáµÄ¼ÓÈë²»µ«ÊµÏÖѪÄÔÆÁÕϸßЧ´©Í¸£¬ £¬£¬£¬£¬£¬¸üͨ¹ý¶àͨ·Ðͬµ÷¿ØÏÔÖø¸ÄÉÆÖ×Áö΢ÇéÐΡ£ ¡£¡£¡£¡£¡£
ͬʱ£¬ £¬£¬£¬£¬£¬°²ÂÞÌæÄáµÄ¿Ú·þ¸øÒ©ÓÅÊÆÔÚÄÔ½ºÖÊÁöÖÎÁÆÖÐÒ²¾ßÓл®Ê±´úÒâÒ壬 £¬£¬£¬£¬£¬°²ÂÞÌæÄáÖÎÁÆÏà¹ØµÄ²»Á¼ÊÂÎñ±¬·¢Âʵͣ¬ £¬£¬£¬£¬£¬Æä¾Ó¼ÒÓÃҩģʽ²»µ«´ó·ù½µµÍ»¼ÕßÒòƵÈÔ¾²ÂöÖÎÁƱ¬·¢µÄÉíÐļ縺ºÍ¾¼Ã¼ç¸º£¬ £¬£¬£¬£¬£¬¸üÍ»ÆÆÁ˹ŰåGBMÖÎÁƶԻ¼ÕßÐж¯ÄÜÁ¦ºÍÕչ˻¤Ê¿ÒÀÀµµÄÏÞÖÆ¡£ ¡£¡£¡£¡£¡£ÓÈÆä¹ØÓÚÉñ¾¹¦Ð§ÊÜËðÈËȺ£¬ £¬£¬£¬£¬£¬ÕâÒ»±ãµ±ÐÔÏÔÖøÌáÉýÁËÖÎÁÆÒ»Á¬ÐÔ£¬ £¬£¬£¬£¬£¬ÎªÑÓÓÀÉúÑÄ»ñÒæµÓÚ¨Á˼áʵµÄÏÖʵ»ù´¡¡£ ¡£¡£¡£¡£¡£ÆÚ´ýÕâÒ»“Öйú¼Æ»®”ÔçÈÕ¸ÄдÏà¹ØÕïÁÆÖ¸ÄÏ£¬ £¬£¬£¬£¬£¬ÎªÄÔ½ºÖÊÁö»¼ÕßµãÁÁÉúÃüÐÂÊï¹â£¡
²Î¿¼ÎÄÏ×£º
[1] OSTROM Q T, PRICE M, NEFF C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019[J]. Neuro Oncol, 2022, 24(Suppl 5):v1-v95.
[2] OSTROM Q T, PRICE M, NEFF C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020[J]. Neuro Oncol, 2023, 25(Supplement_4):iv1-iv99.
[3] STUPP R, MASON W P, VAN DEN BENT M J, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10):987-996.
[4] PINEDA E, DOMENECH M, HERNANDEZ A, et al. Recurrent glioblastoma: ongoing clinical challenges and future prospects[J]. Onco Targets Ther, 2023, 16:71-86.
[5] Shuzhen Lai et al. Anlotinib plus radiotherapy-temozolomide for newly diagnosed glioblastoma: A prospective, multicenter phase II study.. JCO 40, e14020-e14020(2022). DOI:10.1200/JCO.2022.40.16_suppl.e14020
[6] Yuanyuan Chen,Zhongping Chen,et al.Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: Results of a multicenter, double-blind, randomized phase II trial.J Clin Oncol 43, 2025 (suppl 17; abstr LBA2000). DOI:10.1200/JCO.2025.43.17_suppl.LBA2000
ÉùÃ÷£º
1.ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬ £¬£¬£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬ £¬£¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£ ¡£¡£¡£¡£¡£
2.±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£ ¡£¡£¡£¡£¡£
3.±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬ £¬£¬£¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬ £¬£¬£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£ ¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬ £¬£¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£ ¡£¡£¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬ £¬£¬£¬£¬£¬°üÀ¨Óйء¾ÑÎËá°²ÂÞÌæÄὺÄÒ¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬ £¬£¬£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£ ¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬ £¬£¬£¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£ ¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû£¬ £¬£¬£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ï죬 £¬£¬£¬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£ ¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦£¬ £¬£¬£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬ £¬£¬£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£ ¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇó£¬ £¬£¬£¬£¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£ ¡£¡£¡£¡£¡£